Quick Answer
Kyverna Therapeutics, Inc. reported Diluted EPS of $3.64 per share (loss) for fiscal year 2025.
Kyverna Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.64 | -9.3% |
| 2024 | -$3.33 | +96.3% |
| 2023 | -$89.61 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.85 | -6.2% | +12.4% |
| June 30, 2025 | -$0.97 | -44.8% | +5.8% |
| March 31, 2025 | -$1.03 | +8.0% | -28.7% |
| September 30, 2024 | -$0.80 | +96.6% | -19.4% |
| June 30, 2024 | -$0.67 | +96.8% | +40.2% |
| March 31, 2024 | -$1.12 | +90.7% | +95.2% |
| September 30, 2023 | -$23.27 | — | -11.6% |
| June 30, 2023 | -$20.86 | — | -72.4% |
- Kyverna Therapeutics, Inc. showed a decrease of -9.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Kyverna Therapeutics, Inc.’s diluted eps has grown by 95.9% (from $89.61 per share (loss) to $3.64 per share (loss)).
- The most recent figure is from Kyverna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: